Senvest Management LLC Has $6,575,000 Position in BioLineRx Ltd. (BLRX)
Senvest Management LLC maintained its stake in BioLineRx Ltd. (NASDAQ:BLRX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,781,641 shares of the biotechnology company’s stock at the close of the 2nd quarter. Senvest Management LLC owned approximately 12.60% of BioLineRx worth $6,575,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Sabby Management LLC purchased a new stake in BioLineRx during the 1st quarter valued at $3,018,000. KCG Holdings Inc. raised its stake in BioLineRx by 715.9% during the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in BioLineRx during the 1st quarter valued at $126,000. Finally, Citadel Advisors LLC raised its stake in BioLineRx by 443.4% during the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the last quarter. Institutional investors and hedge funds own 32.27% of the company’s stock.
BioLineRx (NASDAQ:BLRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05).
A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research note on Thursday. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $3.00 target price on shares of BioLineRx in a research note on Tuesday, September 12th. ValuEngine lowered shares of BioLineRx from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, Roth Capital set a $3.00 target price on shares of BioLineRx and gave the company a “buy” rating in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $2.83.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Want to see what other hedge funds are holding BLRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLineRx Ltd. (NASDAQ:BLRX).
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.